急性髓系白血病患者MLL融合基因筛查及罕见断裂点病例分析
纳入2021年10月至2023年10月哈尔滨市第一医院血液肿瘤研究中心287例急性髓系白血病(非急性早幼粒细胞白血病)患者,男157例、女130例,中位年龄48岁(19~80岁),筛查56种融合基因及染色体核型,对融合基因阴性而11q23.3易位者行FISH和RNA-seq;MLL融合基因阳性15例,阳性率5.2%,作者认为RNA-seq有助于筛查非常规或新断裂位点融合基因,MLL融合基因阳性患者预后较差。
要点
- 287例AML中MLL融合基因阳性15例,阳性率5.2%。
- 常见融合类型为MLL-ENL(4例)、MLL-ELL(4例)、MLL-AF9(3例)、MLL-AF6(3例)。
- 首疗程CR 6例,2个疗程后CR 8例,CR患者中50% 2个月内复发。
核心结论
- 作者认为RNA-seq技术便于筛查非常规或新断裂位点的融合基因。
- 作者认为MLL融合基因阳性患者预后较差。
研究设计与样本
- 纳入2021年10月至2023年10月哈尔滨市第一医院血液肿瘤研究中心收治的287例AML(非急性早幼粒细胞白血病)患者,男157例、女130例,中位年龄48岁(19~80岁)。
- 287例均行白血病相关56种融合基因筛查和染色体核型分析,对融合基因阴性而染色体存在11q23.3易位者再行荧光原位杂交(FISH)和转录组测序(RNA-seq)检测。
- 观察指标包括缓解、复发等。
主要发现
- 287例AML患者中MLL融合基因阳性15例,阳性率5.2%。
- 检测到11种MLL融合基因类型,常见为MLL-ENL(4例)、MLL-ELL(4例)、MLL-AF9(3例)和MLL-AF6(3例)。
- 15例MLL融合基因阳性患者中2例基因检测阴性而染色体和FISH检测阳性,RNA-seq检测显示1例为MLL融合基因非常见断裂点、1例为新的断裂融合位点。
- MLL融合基因阳性患者化疗首疗程完全缓解(CR)6例,2个疗程后CR 8例,CR患者中50%在2个月内出现复发。
关键数值与推荐
- MLL融合基因阳性率5.2%(15/287)。
- 首疗程CR 6例,2个疗程后CR 8例。
- CR患者中50%在2个月内复发。
临床怎么用
- 作者认为RNA-seq技术便于筛查非常规或新断裂位点的融合基因。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To screen for patients with mixed-lineage leukemia (MLL) fusion gene-positive with acute myeloid leukemia (AML), analyze the clinical characteristics and prognosis of patients with AML with positive fusion genes, and report two cases with rare breakpoint sites. Methods: This study included 287 patients with AML (non-acute promyelocytic leukemia) admitted to the Hematology and Oncology Research Center of Harbin First Hospital from October 2021 to October 2023. The cohort involved 157 males and 130 females, with a median age of 48 years (range: 19-80 years). All 287 patients underwent screening for 56 fusion genes and chromosome karyotyping analysis. Fluorescence in situ hybridization (FISH) and RNA seq were further performed on patients with negative fusion genes but positive 11q23.3 chromosomal translocation. Patient observation indicators included remission, recurrence, and others. Results: Among the 287 patients with AML, 15 were positive for the MLL fusion gene, with a positivity rate of 5.2%. Among the 11 types of MLL fusion genes detected, the most prevalent fusion types were MLL-ENL (4 cases), MLL-ELL (4 cases), MLL-AF9 (3 cases), and MLL-AF6 (3 cases). Of the 15 patients with positive MLL fusion gene, 2 demonstrated negative fusion gene while exhibiting positive chromosome and FISH. RNA-seq testing in these two patients revealed an uncommon breakpoint in the MLL fusion gene and a novel breakpoint fusion site, respectively. Complete remission (CR) was achieved in 6 patients with positive MLL fusion genes during the first chemotherapy cycle. After two cycles, eight patients achieved CR, with 50% of them experiencing recurrence within 2 months. Conclusion: RNA seq technology is useful for screening fusion genes with unconventional or novel cleavage sites, and patients with positive MLL fusion genes demonstrated a poorer prognosis. 目的: 筛查急性髓系白血病(AML)患者中MLL融合基因阳性患者,分析该融合基因阳性AML患者的临床特征和预后,并报道2例罕见断裂位点病例。 方法: 纳入2021年10月至2023年10月哈尔滨市第一医院血液肿瘤研究中心收治的287例AML(非急性早幼粒细胞白血病)患者。男157例,女130例,中位年龄48(19~80)岁。287例患者均进行了白血病相关56种融合基因筛查和染色体核型分析,对融合基因阴性而染色体存在11q23.3易位患者再进行荧光原位杂交(FISH)和转录组测序(RNA-seq)检测。观察指标包括缓解、复发等。 结果: 287例AML患者中,MLL融合基因阳性患者15例,阳性率为5.2%。在检测的MLL融合基因的11种类型中,常见融合类型为MLL-ENL(4例)、MLL-ELL(4例)、MLL-AF9(3例)和MLL-AF6(3例)。15例MLL融合基因阳性患者中两例基因检测阴性而染色体和FISH检测阳性,对这两例患者进行RNA-seq检测,1例为MLL融合基因非常见断裂点,1例为新的断裂融合位点。MLL融合基因阳性患者化疗首疗程完全缓解(CR)6例,2个疗程后CR 8例,CR患者中50% 2个月内出现复发。 结论: RNA-seq技术便于筛查非常规或新断裂位点的融合基因,MLL融合基因阳性患者预后较差。.
引用
- Li S, Cheng HC, Wang ZY, et al. [Screening of MLL fusion genes and rare breakpoint cases in patients with acute myeloid leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 40425457. doi:10.3760/cma.j.cn121090-20240407-00125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。